Recent Posts

Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx as a potential treatment in a JIA population at EULAR 2021

,

Phase III JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing significantly longer time to flare (longer time to worsening of symptoms1) vs. placebo (P

Read Post →